



## PRESS RELEASE

### **CARMAT has recently participated in two scientific conferences**

- A presentation on the use of digital technology in the Company's total artificial heart project at the French American Biotech Symposium (FABS 2012) in Nice, France.
- A presentation at the Techno College of the 25<sup>th</sup> Annual Meeting of the European Association for Cardio-Thoracic Surgery in Barcelona, Spain.

#### **Paris, 29 October 2012**

CARMAT (FR0010907956, ALCAR), the designer and developer of the world's most advanced total artificial heart project, providing an alternative for people suffering from terminal heart failure, announces that it has presented scientific publications at the French American Biotech Symposium (FABS 2012) in Nice on 25 October and the Techno College of the 26<sup>th</sup> Annual Meeting of the European Association for Cardio-Thoracic Surgery (EACTS) in Barcelona on 27 October, 2012.

- **Presentation on the theme of the “Contribution of digital technology to maintaining the autonomy of elderly patients” at FABS 2012, in Nice**

This presentation was given by Mr Marcello Conviti, CARMAT's CEO, on Thursday 25 October 2012 during a session devoted to implants and biomedical engineering. It notably covered preoperative planning systems using 3D modelling, physiological self-regulation algorithms and systems intended to boost the mobility and autonomy of implanted patients.

The 2012 Symposium was organised by Eurobiomed (the healthcare competitive cluster for the French regions of Provence-Alpes-Côte d'Azur and Languedoc-Roussillon) and the Office for Science and Technology of the Consulate General of France in Los Angeles.

- **CARMAT was chosen by the EACTS New Technologies committee for a presentation at the Techno College, the day the conference devotes to innovation, in Barcelona**

This presentation was given by Dr Piet Jansen, CARMAT's Chief Medical Officer, on Saturday 27 October 2012 during a session devoted to innovative devices for treating heart failure. It reported on the specificities of CARMAT's total artificial heart project and on the procedural aspects assessed within the framework of animal testing.

*“We are particularly honoured to have been invited, by the EACTS New Technologies committee, to present our project at the prestigious Techno College”, said Dr Jansen. “This honour reflects the substantial enthusiasm shown by European cardio-thoracic surgery specialists for innovation in the field of chronic heart failure”.*

#### **About CARMAT: CARMAT, the world's most advanced total artificial heart project**

**The only credible response for all cases of end-stage heart failure - a true public health issue:** CARMAT's ultimate aim is to provide a response to a major public health issue associated with cardiovascular disease, the world's leading cause of death: heart failure. This disease currently affects over 20 million patients in Europe and the United States. By pursuing the development of its total artificial heart, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from end-stage heart failure.

**The result of combining two types of unique expertise:** the medical expertise of Professor Carpentier, known throughout the world for inventing Carpentier-Edwards® heart valves - most widely used worldwide - and the technological expertise of EADS, a global aerospace leader.

**Imitating the natural heart:** Given its size and weight, the choice of structural materials and its innovative physiological functions, CARMAT's total artificial heart could, assuming upcoming clinical trials are successful, potentially benefit tens of thousands of patients a year – with no risk of rejection and providing them with unparalleled quality of life.

**A project leader acknowledged at the European level:** with the backing of the European Commission, CARMAT has received the largest grant-in-aid (a total of €33m) made to an SME by OSEO (the French state innovation agency).

**Strongly committed, prestigious founders and shareholders:** Truffle Capital (the leading European venture capital firm), EADS, the Foundation Alain Carpentier, the Marie Lannelongue Cardiothoracic Centre and thousands of institutional and individual shareholders have placed their trust in CARMAT.

For further information, visit: [www.carmatsa.com](http://www.carmatsa.com)

#### About FABS 2012:

The French American Biotech Symposium was first launched in 2008 by the Office for Science and Technology of the French Embassy in the United States and is held each year, alternating between France and the United States. It aims to promote the exchange of information in terms of innovation in ICT health, telemedicine, bioengineering, implants, etc. It also strives to develop networking between French and American experts in these fields and encourage innovative public-private partnerships between France and the United States. It targets researchers and scientists from these two countries who are involved in Research & Development projects, as well as entrepreneurs and representatives of the ICT and pharmaceutical sectors.

For further information, visit: [www.fabs2012.com](http://www.fabs2012.com)

•••

#### Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe to, shares in CARMAT ("the Company") in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based solely on the current expectations and assumptions of the Company's management and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. The Company's objectives as mentioned in this press release may not be achieved for any of these reasons or due to other risks and uncertainties. No guarantee can be given as to any of the events anticipated by the forward-looking statements, which are subject to inherent risks, including those described in the *Document de Référence* registered with the *Autorité des Marchés Financiers* under number R.12-044 on September 12, 2012 and the *Note d'Opération* that was approved with visa no. 11-308 on July 11, 2011, changes in economic conditions, the financial markets or the markets in which Carmat operates. In particular, no guarantee can be given concerning the Company's ability to finalize the development, validation and industrialization of the prosthesis and the equipment required for its use, to manufacture the prostheses, satisfy the requirements of the AFSSAPS, enroll patients, obtain satisfactory clinical results, perform the clinical trials and tests required for CE marking and to obtain the CE mark.

•••

**CARMAT**  
**Marcello Conviti**  
CEO

**Patrick Coulombier**  
COO

**Valérie Leroy**  
Marketing and Investor  
Relations Director  
Tel: +33 (0)1 39 45 64 50  
[contact@carmatsas.com](mailto:contact@carmatsas.com)

**Alize RP**  
Press Relations

**Caroline Carmagnol**  
Tel: +33 (0)6 64 18 99 59  
[caroline@alizerp.com](mailto:caroline@alizerp.com)

**NewCap.**  
Financial communication  
and investor relations

**Dusan Oresansky /  
Emmanuel Huynh**  
Tel: +33 (0)1 44 71 94 94  
[carmat@newcap.fr](mailto:carmat@newcap.fr)



Name: **CARMAT**  
ISIN code: **FR0010907956**  
Ticker: **ALCAR**